Markets:

Overview

News

Currencies

International

Treasuries

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.423 +0.253 (+11.65%)

Streaming Delayed Price Updated: 3:19 PM EST, Dec 22, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

38 39 Next >

3 Short-Squeeze Stocks to Keep on Your Radar ↗

March 09, 2023

These three short-squeeze stocks are each options investors may want to consider as companies with near-term catalysts that could run.

Via InvestorPlace

Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock ↗

March 09, 2023

Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule.

Via InvestorPlace

Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket ↗

March 09, 2023

Gainers

Via Benzinga

Tesla, Apple, Cassava Sciences, MongoDB, Asana: Why These Five Stocks Are Drawing Investors' Attention Today? ↗

March 08, 2023

Via Benzinga

Why Cassava Sciences Stock Is Surging After Hours ↗

March 08, 2023

Cassava Sciences Inc (NASDAQ: SAVA) shares are rising in extended trading Wednesday in the wake of recent insider buying.

Via Benzinga

3 Big Reasons to Sell Cassava Sciences Stock Right Now ↗

February 01, 2023

It isn't about running out of money, but it's still laden with risk.

Via The Motley Fool

If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today ↗

January 31, 2023

Via Benzinga

Why Is Cassava Sciences (SAVA) Stock Down 20% Today? ↗

January 24, 2023

Here's why shares of Cassava Sciences and SAVA stock are on the decline today, amid a relatively calm day overall.

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 08, 2023

Via Benzinga

Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates

February 28, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End ↗

February 24, 2023

These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch.

Via InvestorPlace

Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease

February 08, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

$100 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much Today ↗

January 18, 2023

Via Benzinga

Cassava Sciences Stock Undervalued with Its $124 Price Target?

January 30, 2023

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

Via MarketBeat

Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

January 24, 2023

Major Wall Street indices closed mixed on Tuesday as a disparate set of corporate earnings dampened the existing euphoria over the possibility of a slowdown in rate hikes.

Via Benzinga

Cassava Sciences Stock Is Diving: What's Going On? ↗

January 24, 2023

Cassava Sciences Inc (NASDAQ: SAVA) shares are trading significantly lower Tuesday after the company announced top-line clinical results from a Phase 2 study

Via Benzinga

Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 24, 2023

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 24, 2023

Via Benzinga

Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease ↗

January 24, 2023

Via Benzinga

Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors ↗

January 24, 2023

Some patients improved while taking the company's twice-daily pill.

Via Investor's Business Daily

3M, Magna International And Other Big Stocks Moving Lower On Tuesday ↗

January 24, 2023

U.S. stocks traded mostly higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast ↗

January 24, 2023

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.31% to 33,524.12 while the NASDAQ fell...

Via Benzinga

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

January 24, 2023

From Cassava Sciences, Inc.

Via GlobeNewswire

Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock? ↗

January 11, 2023

Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock.

Via InvestorPlace

Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish ↗

January 11, 2023

2023 can be the year of biotechs after two consecutive years of negative or barely positive returns.

Via Talk Markets

SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday ↗

January 06, 2023

Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to

Via Benzinga

Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session ↗

December 22, 2022

Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD

December 20, 2022

From Cassava Sciences, Inc.

Via GlobeNewswire

Is Anavex Life Sciences a Buy? ↗

December 13, 2022

It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's.

Via The Motley Fool

Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

December 07, 2022

U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds.

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.